{
 "name": "漢達",
 "slug": "tw-6620",
 "aliases": [
  "漢達生技醫藥股份有限公司",
  "Handa Pharma",
  "6620"
 ],
 "ticker": "6620",
 "industry": "生技醫療業",
 "website": "http://www.handapharma.com.tw",
 "summary": "漢達（6620）是上櫃的生技醫療類股公司，2014 年成立，2025 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "漢達生技醫藥股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "Handa Pharma",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2025-12-23",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2014-05-08",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "劉芳宇",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "陳俊良",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 1659819000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "http://www.handapharma.com.tw",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 70409,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原基本資料數值、單位、as_of保留；2026-10-22逐欄核對官方月營收API，與原值（百分比四捨五入至二位）一致。官方出表日期：2026-10-17。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": -20.12,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原基本資料數值、單位、as_of保留；2026-10-22逐欄核對官方月營收API，與原值（百分比四捨五入至二位）一致。官方出表日期：2026-10-17。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": -55.9,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原基本資料數值、單位、as_of保留；2026-10-22逐欄核對官方月營收API，與原值（百分比四捨五入至二位）一致。官方出表日期：2026-10-17。"
  },
  {
   "claim": "管線：HND-039（Omcazio）",
   "value": "癌症｜美國FDA最終核准、準備上市｜美國",
   "unit": "",
   "as_of": "2026-09-04",
   "source": "https://handapharma.com.tw/%e9%87%8d%e5%a4%a7%e8%a8%8a%e6%81%af-%e4%bb%a3%e5%ad%90%e5%85%ac%e5%8f%b8-handa-oncology-llc-%e5%85%ac%e5%91%8a%e6%b2%bb%e7%99%82%e7%99%8c%e7%97%87%e4%b9%8b505b2-%e6%96%b0%e8%97%a5-hnd-039-omcazi-2/",
   "note": "核准日為美國時間2026-09-03；本筆as_of為官網發布2026-09-04；未將準備上市當成已上市。"
  },
  {
   "claim": "管線：HND-032（varenicline）",
   "value": "戒菸輔助｜美國FDA ANDA最終核准｜美國",
   "unit": "",
   "as_of": "2025-05-22",
   "source": "https://handapharma.com.tw/%e4%bb%a3%e5%ad%90%e5%85%ac%e5%8f%b8handa-pharmaceuticals-llc%e5%85%ac%e5%91%8a%e6%88%92%e8%8f%b8%e8%bc%94%e5%8a%a9%e5%8a%91hnd-032%e9%80%9a%e9%81%8e%e7%be%8e%e5%9c%8bfda%e5%ad%b8%e5%90%8d%e8%97%a5/",
   "note": "核准日為美國時間2025-05-21；原料與商品均不等同Chantix品牌。"
  },
  {
   "claim": "管線：HND-033（Vysentri；dasatinib capsule）",
   "value": "癌症｜停止原NDA審查、不再回覆CRL｜美國",
   "unit": "",
   "as_of": "2025-09-19",
   "source": "https://handapharma.com.tw/%e8%a3%9c%e5%85%85113-10-22%e4%b9%8b%e9%87%8d%e8%a8%8a%e4%bb%a3%e5%ad%90%e5%85%ac%e5%8f%b8handa-oncology%e5%85%ac%e5%91%8ahnd-033%e6%96%bc%e7%be%8e%e5%9c%8bfda%e4%b9%8b%e6%9f%a5%e9%a9%97%e7%99%bb/",
   "note": "不把同成分Phyrago錠劑的核准移用至HND-033膠囊。"
  },
  {
   "claim": "管線：Phyrago（dasatinib）",
   "value": "慢性骨髓性白血病及急性淋巴性白血病｜美國FDA最終核准｜美國",
   "unit": "",
   "as_of": "2025-04-20",
   "source": "https://handapharma.com.tw/%e4%bb%a3%e5%ad%90%e5%85%ac%e5%8f%b8handa-therapeutics-llc%e5%85%ac%e5%91%8a%e7%b0%bd%e8%a8%82%e6%b2%bb%e7%99%82%e8%a1%80%e7%99%8c%e4%b9%8b505b2%e6%96%b0%e8%97%a5-phyrago%e4%b9%8b%e7%be%8e/",
   "note": "本來源發布時為上市準備階段；適應症亦見2025-01-01同產品資產取得公告。"
  },
  {
   "claim": "授權合作：Phyrago",
   "value": "Cycle Pharmaceuticals Ltd.｜美國｜2025-04-18",
   "unit": "",
   "as_of": "2025-04-20",
   "source": "https://handapharma.com.tw/%e4%bb%a3%e5%ad%90%e5%85%ac%e5%8f%b8handa-therapeutics-llc%e5%85%ac%e5%91%8a%e7%b0%bd%e8%a8%82%e6%b2%bb%e7%99%82%e8%a1%80%e7%99%8c%e4%b9%8b505b2%e6%96%b0%e8%97%a5-phyrago%e4%b9%8b%e7%be%8e/",
   "note": "採正文明列的美國簽字日，不採事實發生日4月19日或官網發布日4月20日。"
  },
  {
   "claim": "授權合作：TASCENSO ODT",
   "value": "Cycle Pharmaceuticals Ltd.｜美國｜2022-03-04",
   "unit": "",
   "as_of": "2022-03-07",
   "source": "https://handapharma.com.tw/agreement-with-cycle/",
   "note": "5600萬美元含簽約金及里程碑總額，未拆算任一金額分項；毛利分成非已知百分比。"
  },
  {
   "claim": "權利金比率：Phyrago（給付Xspray）",
   "value": "不超過10",
   "unit": "%",
   "as_of": "2025-08-12",
   "source": "https://handapharma.com.tw/%e4%bb%a3%e5%ad%90%e5%85%ac%e5%8f%b8handa-therapeutics-llc%e5%85%ac%e5%91%8a%e8%88%87xspray-pharma-ab%e7%b0%bd%e8%a8%82%e5%b0%88%e5%88%a9%e6%8e%88%e6%ac%8a%e5%90%88%e7%b4%84%ef%bc%8c%e4%bb%a5/",
   "note": "付款方向：漢達子公司付給Xspray；計價基礎為對外授權現金流入Net Proceeds，非產品淨銷售額；附合意條件。"
  },
  {
   "claim": "管線：HND-045（學名未公開）",
   "value": "神經系統疾病｜共同開發中｜美國",
   "unit": "",
   "as_of": "2024-12-17",
   "source": "https://handapharma.com.tw/%e9%87%8d%e5%a4%a7%e8%a8%8a%e6%81%af-%e6%9c%ac%e5%85%ac%e5%8f%b8%e5%8f%8a%e5%ad%90%e5%85%ac%e5%8f%b8handa-neuroscience-llc%e8%88%87%e6%98%93%e5%a8%81%e7%94%9f%e9%86%ab%e5%8f%8atulex-pharmaceuticals-i/",
   "note": "公開稿未揭露具體期別，不自行寫為臨床期別。"
  },
  {
   "claim": "授權合作：Phyrago（Xspray專利授權）",
   "value": "Xspray Pharma AB｜依Phyrago不同區域授權及雙方約定（未列固定地域）｜2025-08-12",
   "unit": "",
   "as_of": "2025-08-12",
   "source": "https://handapharma.com.tw/%e4%bb%a3%e5%ad%90%e5%85%ac%e5%8f%b8handa-therapeutics-llc%e5%85%ac%e5%91%8a%e8%88%87xspray-pharma-ab%e7%b0%bd%e8%a8%82%e5%b0%88%e5%88%a9%e6%8e%88%e6%ac%8a%e5%90%88%e7%b4%84%ef%bc%8c%e4%bb%a5/",
   "note": "付款方向：漢達子公司付給Xspray；計價基礎為對外授權現金流入Net Proceeds，非產品淨銷售額；附合意條件。 Handa Therapeutics取得Xspray專利授權，依不同區域授權與合意條件給付不超過Phyrago淨收益10%的權利金；Net Proceeds是產品對外授權現金流入，非淨銷售額。與授出Cycle美國銷售權屬不同契約。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6620.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}